Drug reference

Ozogamicin

Monoclonal Antibody · Antineoplastic

Also known as Gemtuzumab ozogamicin, Inotuzumab ozogamicin, MYLOTARG

Monoclonal AntibodyAntineoplastic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

and reproductive function in

FDA category + note

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
AmiodaroneSevereDatabaseDDInter
AmisulprideSevereDatabaseDDInter
AnagrelideSevereDatabaseDDInter

Mechanism

Ozogamicin is the cytotoxic component of antibody-drug conjugates. The antibody component (e.g., gemtuzumab or inotuzumab) targets specific tumor antigens (e.g., CD33 or CD22) and facilitates internalization into tumour cells. Once inside, ozogamicin (a calicheamicin derivative) is cleaved and causes double-strand breaks in DNA, leading to cell cycle arrest and apoptotic cell death.

Indications

CD33-positive acute myeloid leukaemia (specialist use only)Relapsing or treatment-refractory acute B-cell lymphoblastic leukemia (B-ALL) in adults

Dosing

Adult: l INDICATIONS AND DOSE Immune system and malignant disease 8 Multiple myeloma in patients who have received at least one prior therapy (in combination with lenalidomide and dexamethasone) (specialist use only) Gemtuzumab ozogamicin 17-Oct-2018 Gemtuzumab ozogamicin is a monoclonal antibody that binds to CD33-expressing tumour cells to induce cell cycle arrest and apoptotic cell death.…